Literature DB >> 5774048

Metabolism and exretion of 3-hydroxyphenyltrimethylammonium and neostigmine.

M A Husain, J B Roberts, B H Thomas, A Wilson.   

Abstract

1. Carbon-14 labelled 3-hydroxyphenyltrimethylammonium (3-OH PTMA), an active metabolite of neostigmine, has been given to rats by intramuscular injection and its excretion, distribution and metabolism have been studied.2. A method is described for the separation and estimation of free and conjugated 3-OH PTMA in urine and liver.3. In the first hour, about 20% of a dose is excreted in the urine as free 3-OH PTMA and thereafter the rate of excretion of glucuronide conjugate exceeds that of free 3-OH PTMA. In 24 hr 76.8% of the dose is excreted in urine mainly as the conjugate.4. The peak concentration of radioactivity in blood occurs within 30 min and in liver within 1 hr after administration. More than 90% of the radioactivity in liver occurs as the glucuronide conjugate. Relatively high concentrations of radioactivity were found in liver and heart.5. In the hen 3-OH PTMA is rapidly excreted by renal tubular secretion.6. Experiments with carbon-14 labelled neostigmine show that up to 1 hr mainly unchanged neostigmine is excreted in urine; thereafter increasing amounts of free 3-OH PTMA and its glucuronide conjugate are excreted.7. It is concluded that the duration of action of neostigmine is determined by its rapid renal excretion and by its metabolism to the glucuronide conjugate of 3-OH PTMA.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5774048      PMCID: PMC1703206          DOI: 10.1111/j.1476-5381.1969.tb07994.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  6 in total

1.  The action of eserine-like and curare-like substances on the responses of frog's nerve-muscle preparations to repetitive stimulation.

Authors:  S L Cowan
Journal:  J Physiol       Date:  1938-08-15       Impact factor: 5.182

2.  Studies on the inter-relationship of certain cholinergic compounds. V. The significance of the actions of the 3-hydroxy phenyltrimethylammonium ion on neuromuscular function.

Authors:  W F RIKER; W C WESCOE
Journal:  J Pharmacol Exp Ther       Date:  1950-12       Impact factor: 4.030

3.  Pharmacological properties of some neostigmine analogs.

Authors:  L O RANDALL; G LEHMANN
Journal:  J Pharmacol Exp Ther       Date:  1950-05       Impact factor: 4.030

4.  Metabolism of neostigmine in vitro.

Authors:  J B Roberts; B H Thomas; A Wilson
Journal:  Biochem Pharmacol       Date:  1968-01       Impact factor: 5.858

5.  Evaluation of curarizing drugs in man. V. Antagonism to curarizing effects of d-tubocurarine by neostigmine, m-hydroxy phenyltrimethylammonium and m-hydroxy phenylethyldimethylammonium.

Authors:  D W MacFARLANE; E W PELIKAN; K R UNNA
Journal:  J Pharmacol Exp Ther       Date:  1950-11       Impact factor: 4.030

6.  Metabolism of [14C]-neostigmine in the rat.

Authors:  J B Roberts; B H Thomas; A Wilson
Journal:  Br J Pharmacol Chemother       Date:  1965-12
  6 in total
  4 in total

1.  The relationship between the pharmacokinetics, cholinesterase inhibition and facilitation of twitch tension of the quaternary ammonium anticholinesterase drugs, neostigmine, pyridostigmine, edrophonium and 3-hydroxyphenyltrimethylammonium.

Authors:  H E Barber; T N Calvey; K T Muir
Journal:  Br J Pharmacol       Date:  1979-08       Impact factor: 8.739

Review 2.  Clinical pharmacokinetics of cholinesterase inhibitors.

Authors:  S M Aquilonius; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

3.  The pharmacokinetics of neostigmine and 3-hydroxyphenyltrimethyl- ammonium in the rat: dose-dependent effects after portal vein administration.

Authors:  H E Barber; G R Bourne
Journal:  Br J Pharmacol       Date:  1974-12       Impact factor: 8.739

4.  Effects of Sugammadex and Neostigmine on Renal Biomarkers.

Authors:  Yasemin Isik; Onur Palabiyik; Bilal Muhammed Cegin; Ugur Goktas; Ismail Kati
Journal:  Med Sci Monit       Date:  2016-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.